Fewer than 40% of women suffering from bad cholesterol are able to follow the medicines regiment needed to control their disease, according to a US survey.
The poll was conducted by Women Heart, the National Coalition for Women with Heart Disease, a non-profit organisation. This is the first national survey of this kind in the United States.
It showed that the mean medication adherence rate for the 795 women who took part in the survey was only 62%.
It’s a dilemma that many tech startups face: How quickly should they expand beyond their first product? Adding new products and services might help grow sales, but young, small companies need to be careful that they don’t bite off more than they can chew.
Milwaukee healthcare technology startup Mpirik wrestled with that question, and decided to waste no time in pushing ahead with multiple products at a relatively early stage. “It made more and more sense” as company leaders realized their three software products are “very much symbiotic,” CEO Sue Ela says.
Los ingresos de Grifols han aumentado un 22,4%, hasta los 3.355 millones de euros, después de la adquisición de la unidad de diagnóstico de transfusiones de Novartis.
L'équipe de recherche du Pr. Noriyuki Azuma, du National Center for Child Health and Development, a réalisé une première mondiale en réussissant à créer des cellules ganglionnaires de la rétine (RGC) à partir de cellules-souches iPS.
Jusqu'ici, aucun laboratoire n'avait réussi à produire des axones à partir de cellules-souches iPS, car ces cellules longues et fibreuses sont difficiles à cultiver. La méthode conçue par les chercheurs japonais permet d'obtenir en 30 jours des cellules RGC fonctionnelles et mesurant de 1 à 2 cm de long, ce qui est proche des longueurs naturelles et permet ainsi de réaliser des tests pharmaceutiques et d'autres études pour mieux comprendre les mécanismes des pathologies de l'oeil.
Women’s health-focused biopharmaceutical researcher Evestra is taking a $5 million loan from existing partner Gedeon Richter so that it can further develop a product line that includes a potential birth control device similar to NuvaRing.
L'équipe du professeur Luke O'Neill, président du Département de biochimie du Trinity Biomedical Sciences Institute, a identifié un nouveau médicament qui pourrait être capable de stopper la progression de maladies comme la sclérose en plaques, la maladie d'Alzheimer, l'arthrite rhumatoïde et d'autres maladies inflammatoires.
Une équipe de recherche menée par Miguel Soares de l'Instituto Gulbenkian de Ciência (IGC) au Portugal a découvert qu'une bactérie vivant dans l'intestin serait un mécanisme de défense naturel contre la transmission de la malaria.
Unchained Labs can now say it has financial stability after raising $25 million in Series A funding from venture capital investors Novo Ventures, Canaan Partners, and TPG Biotech.
What it still must prove is that its newly acquired first product, Optim, can provide its customers with stability, too.
Hospitals often try to improve their services by getting direct feedback from customers—their patients. But even when patient surveys are electronic, many patients decline to respond to all of the questions, if they bother to respond at all.
Houston’s Fannin Innovation Studio has spun out its latest company, a biotech called Acelerox that aims to use nanoparticle technology to treat a variety of autoimmune and other disorders.
Acelerox has been formed out of a licensing deal with Rice University. It’s based on novel nanoparticles developed by James Tour, a synthetic chemist and a Rice professor.
Atul Varadhachary, Fannin’s managing partner and the president of Acelerox, told me that the nanoparticles—known as PEG-HCC, or pegylated-hydrophilic carbon clusters—may have broad potential. They might help fight a number of autoimmune diseases like multiple sclerosis and rheumatoid arthritis, and even injuries from strokes or traumatic brain injury.
